Brightonix Imaging Demonstrates Excellence in AI-Based Dopamine PET Quantification
- Post by
- Admin
- Date
- 2025-12-10
Brightonix Imaging Demonstrates Excellence of AI-Based Dopamine PET Quantification
Technology Enables Dopamine Transporter PET Quantification Without MRI
Brightonix Imaging has demonstrated the superior quantitative performance of its AI-based PET image quantification software, BTXBrain, through the research paper titled “Accurate Automated Quantification of Dopamine Transporter PET Without MRI Using Deep Learning-based Spatial Normalization,” published in Nuclear Medicine & Molecular Imaging (NMMI).
The company announced that this study earned the NMMI Outstanding Research Award at the 2025 Autumn Conference of the Korean Society of Nuclear Medicine (KSNM), held from November 14–15 at KINTEX in Ilsan.
Conducted in collaboration with Professor Hongyoon Choi (Department of Nuclear Medicine, Seoul National University Hospital) and Professor Yu Kyeong Kim (Department of Nuclear Medicine, Seoul Metropolitan Government – Seoul National University Boramae Medical Center), the study was published in the July 2024 issue of NMMI. It received significant attention for introducing a deep learning–based normalization method that enables dopamine transporter PET quantification without MRI, offering a substantial improvement in both the accuracy and convenience of automated quantification.
Traditionally, MRI data has been essential for accurate dopamine transporter PET quantification. In this study, however, the research team successfully developed an image analysis solution capable of performing high-precision spatial normalization using only PET images, providing meaningful clinical benefits—particularly in cases where MRI scans are difficult or impractical.
Seung Kwan Kang, Head of AI/Algorithm Development at Brightonix Imaging, stated, “This award acknowledges that our technology addresses clinically meaningful challenges and contributes to real-world medical practice. We will continue advancing AI-based nuclear medicine image quantification to establish new standards in the diagnosis and treatment assessment of Parkinson’s disease.”
Brightonix Imaging is a leading innovator in Positron Emission Tomography (PET) and AI-driven medical image analysis technologies, providing cutting-edge solutions for clinical and research applications.
Source: 브라이토닉스이미징, AI 기반 도파민 PET 정량화 기술의 우수성 입증 - 한국의약통신(http://www.kmpnews.co.kr)